嵌合抗原受体T细胞用于系统性红斑狼疮治疗的策略与研究进展

系统性红斑狼疮(SLE)是一种以产生一系列自身抗体为特征的慢性自身免疫性疾病。目前,SLE尚不能根治,糖皮质激素等药物治疗是临床治疗SLE的主要方法,但会产生严重的不良反应。近年来,嵌合抗原受体T细胞(CAR-T)免疫疗法作为血液肿瘤的新型治疗方法已被证实效果显著。CAR-T细胞通过识别结合SLE中分泌自身抗体的B细胞的特异性表面标志进行研究设计,以精准杀伤上述“坏”B细胞,达到减少甚至避免自身抗体产生的目的,从而改善患者病情。本文将从B细胞表面标志物出发,探讨CAR-T细胞用于治疗SLE的机制及研究进展,为探索SLE治愈性方法提供新的思路。

Strategy and research progress of chimeric antigen receptor T cells in the treatment of systemic lupus erythematosus

Systemic lupus erythematosus(SLE)is a chronic autoimmune disease characterized by the production of a series of autoantibodies.At present,SLE can not be cured.Glucocorticoids and other drugs are the main methods of clinical treatment of SLE,but they will produce serious adverse reactions.In recent years,the chimeric antigen receptor T cell(CAR-T)immunotherapy has been proved to be effective as a new treatment for blood tumors.CAR-T cells are designed by identifying the specific surface markers of B cells that secrete autoantibodies in SLE,so as to kill the above"bad"B cells precisely,reduce or even avoid the production of autoantibodies,so as to improve the patient′s condition.In this paper,the mechanism and research progress of CAR-T cells in the treatment of SLE will be discussed based on B cell surface markers,so as to provide new ideas for the exploration of the therapeutic methods of SLE.